Much of the talk in the Pharma industry has been the focus on the growth in the Asia Pacific region. The country of Malaysia is no different. According to Business Times, it's one of the fastest and stablest countries in the region, and there is a growing presence of the Pharmaceutical industry, with a focus on manufacturing, as a result. With presences of companies such as Ranbaxy, Cipla, Dr. Reddy's Labs, Biocon and Strides Arcolab, many others are poised to enter the region. The Malaysian government is also looking at incentives to offer companies such as faster registration of products and quicker market entry. Could this incentivise even more Pharma companies to explore the region for opportunities.
This April at Partnerships in Clinical Trials, one of our core focuses will be emerging regions for Pharmaceuticals and Clinical Trials. During the session "Clinical Trials in the Asia-Pacific Region: Roadblocks and Opportunities," panelists from Takeda Pharmaceuticals, Mitsubishi Tanabe Pharma America and LabCorp Clinical Trials will be gathering to discuss the opportunities and setbacks this region features for clinical trials and Pharmaceutical expansion. For more information on this session and the rest of the event, download the brochure. If you'd like to join us, register today and mention code XP1800BLOG to save 15% off the standard rate!
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to firstname.lastname@example.org.